Ascletis Pharma Inc. has announced its intention to conduct a share repurchase under its existing Repurchase Mandate. The company stated that any repurchase will be subject to market conditions and at the absolute discretion of the Board. As of the date of the announcement, no shares have been repurchased. The timing, quantity, and price of any repurchase have not been specified, and there is no assurance that any repurchase will be made. The company emphasized that shareholders and potential investors should exercise caution when dealing in its shares. The currency for any potential transaction was not specified in the announcement.